162 related articles for article (PubMed ID: 35901948)
21. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients.
van Hoogstraten LMC; van Gennep EJ; Kiemeney LALM; Witjes JA; Voskuilen CS; Deelen M; Mertens LS; Meijer RP; Boormans JL; Robbrecht DGJ; Beerepoot LV; Verhoeven RHA; Ripping TM; ; van Rhijn BWG; Aben KKH; Hermans TJN
World J Urol; 2022 Jan; 40(1):111-118. PubMed ID: 34585294
[TBL] [Abstract][Full Text] [Related]
22. The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis.
Bruins HM; Aben KK; Arends TJ; van der Heijden AG; Witjes AJ
Urol Oncol; 2016 Apr; 34(4):166.e1-6. PubMed ID: 26705102
[TBL] [Abstract][Full Text] [Related]
23. Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment.
Shariat SF; Ehdaie B; Rink M; Cha EK; Svatek RS; Chromecki TF; Fajkovic H; Novara G; David SG; Daneshmand S; Fradet Y; Lotan Y; Sagalowsky AI; Clozel T; Bastian PJ; Kassouf W; Fritsche HM; Burger M; Izawa JI; Tilki D; Abdollah F; Chun FK; Sonpavde G; Karakiewicz PI; Scherr DS; Gonen M
Eur Urol; 2012 Feb; 61(2):237-42. PubMed ID: 22033174
[TBL] [Abstract][Full Text] [Related]
24. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
[TBL] [Abstract][Full Text] [Related]
25. The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate.
Frazier HA; Robertson JE; Dodge RK; Paulson DF
Cancer; 1993 Jun; 71(12):3993-4001. PubMed ID: 8508365
[TBL] [Abstract][Full Text] [Related]
26. The role of preoperative prostatic urethral biopsy in clinical decision-making at the time of radical cystectomy.
Gaya JM; Matulay J; Badalato GM; Holder DD; Hruby G; McKiernan J
Can J Urol; 2014 Apr; 21(2):7228-33. PubMed ID: 24775577
[TBL] [Abstract][Full Text] [Related]
27. What is the ratio of urethral recurrence risk after radical cystoprostatectomy for bladder cancer?
Sevin G; Soyupek S; Armağan A; Hoşcan MB; Dilmen C; Tükel O
Int Urol Nephrol; 2004; 36(4):523-7. PubMed ID: 15787329
[TBL] [Abstract][Full Text] [Related]
28. Is stage pT4a (D1) reliable in assessing transitional cell carcinoma involvement of the prostate in patients with a concurrent bladder cancer? A necessary distinction for contiguous or noncontiguous involvement.
Pagano F; Bassi P; Ferrante GL; Piazza N; Abatangelo G; Pappagallo GL; Garbeglio A
J Urol; 1996 Jan; 155(1):244-7. PubMed ID: 7490845
[TBL] [Abstract][Full Text] [Related]
29. Development and Internal Validation of a Nomogram Predicting Overall Survival Based on Log ODDS of Positive Lymph-Nodes for Post Radical Cystectomy Patients in Muscle Invasive Carcinoma of Bladder.
Patel KN; Salunke A; Sharma M; Puj K; Rathod P; Warikoo V; Bakshi G; Pandya SJ
Clin Genitourin Cancer; 2023 Jun; 21(3):e153-e165. PubMed ID: 36549982
[TBL] [Abstract][Full Text] [Related]
30. Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy.
Koie T; Ohyama C; Yamamoto H; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Kitayam M; Hirota K
Urol Oncol; 2014 Aug; 32(6):820-5. PubMed ID: 24951323
[TBL] [Abstract][Full Text] [Related]
31. Risk factors and oncological outcomes of urethral recurrence in male patients with muscle invasive bladder cancer after radical cystectomy combined with urinary diversion: a propensity score-matched case control study.
Yao Z; Jiang Y; Zhu X; Wu B; Bai S
Int J Clin Oncol; 2020 Jul; 25(7):1377-1384. PubMed ID: 32318904
[TBL] [Abstract][Full Text] [Related]
32. Preoperative chemotherapy in clinically node positive muscle invasive bladder cancer: Radiologic variables can predict response.
Ghodoussipour S; Xu W; Tran K; Atkinson R; Cho D; Miranda G; Cai J; Bhanvadia S; Schuckman A; Daneshmand S; Djaladat H
Urol Oncol; 2021 Feb; 39(2):133.e1-133.e8. PubMed ID: 32900621
[TBL] [Abstract][Full Text] [Related]
33. Pilot Study of [
Eulitt PJ; Altun E; Sheikh A; Wong TZ; Woods ME; Rose TL; Wallen EM; Pruthi RS; Smith AB; Nielsen ME; Whang YE; Kim WY; Godley PA; Basch EM; David GU; Ramirez J; Deal AM; Rathmell WK; Chen RC; Bjurlin MA; Lin W; Lee JK; Milowsky MI
Clin Genitourin Cancer; 2020 Oct; 18(5):378-386.e1. PubMed ID: 32147364
[TBL] [Abstract][Full Text] [Related]
34. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
Necchi A; Anichini A; Raggi D; Briganti A; Massa S; Lucianò R; Colecchia M; Giannatempo P; Mortarini R; Bianchi M; Farè E; Monopoli F; Colombo R; Gallina A; Salonia A; Messina A; Ali SM; Madison R; Ross JS; Chung JH; Salvioni R; Mariani L; Montorsi F
J Clin Oncol; 2018 Dec; 36(34):3353-3360. PubMed ID: 30343614
[TBL] [Abstract][Full Text] [Related]
35. Incidental prostate cancer in patients with bladder urothelial carcinoma: comprehensive analysis of 1,476 radical cystoprostatectomy specimens.
Bruins HM; Djaladat H; Ahmadi H; Sherrod A; Cai J; Miranda G; Skinner EC; Daneshmand S
J Urol; 2013 Nov; 190(5):1704-9. PubMed ID: 23707451
[TBL] [Abstract][Full Text] [Related]
36. Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder.
Softness K; Kaul S; Fleishman A; Efstathiou J; Bellmunt J; Kim SP; Korets R; Chang P; Wagner A; Olumi AF; Gershman B
Urol Oncol; 2022 Jun; 40(6):272.e1-272.e9. PubMed ID: 35058142
[TBL] [Abstract][Full Text] [Related]
37. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
38. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
[TBL] [Abstract][Full Text] [Related]
39. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
[TBL] [Abstract][Full Text] [Related]
40. Incidence and location of lymph node metastases in patients undergoing radical cystectomy for clinical non-muscle invasive bladder cancer: results from a prospective lymph node mapping study.
Bruins HM; Skinner EC; Dorin RP; Ahmadi H; Djaladat H; Miranda G; Cai J; Daneshmand S
Urol Oncol; 2014 Jan; 32(1):24.e13-9. PubMed ID: 23395238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
